Valo
4 known investors
Find your way into Valo
675 people in our graph share verified history with the Valo team — schools, employers, funds. One of them is your warm intro.
Valo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields. It positions itself as a company focused on reshaping how new drugs are discovered.
Also known as Valo Health
Founders & leadership
Investors · 4
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BJan 2021Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Valo (Valo Health) is a drug discovery and development company that builds an integrated research engine around real-world human data, artificial intelligence, causal inference techniques and predictive chemistry. Its platform has two linked components. The first, described as human causal biology, applies AI/machine learning, advanced causal inference and statistical genetics to large-scale human datasets to identify patient subtypes, map them to biological pathways, and pinpoint and validate targets for therapeutic intervention in human data and human tissue before laboratory experimentation begins. The second, described as closed-loop chemistry, couples computational modeling with laboratory capabilities to search large chemical spaces, generate novel and diverse lead compounds, and refine models after each experimental cycle in order to balance the competing properties required to advance lead series into development candidates.
The company frames its scientific rationale around the high attrition of drugs in clinical development, citing published work that roughly 90% of drugs entering human testing do not reach patients, and attributes much of that failure to insufficient understanding of human biology at the outset rather than to chemistry. Valo's stated aim is to reduce biological risk early, focus chemistry on validated targets, and pursue novel, potentially first-in-class small molecules against targets that are difficult to address with conventional approaches. Teams are organized to work jointly across biology, chemistry and engineering rather than in separate functions.
Business model
Valo positions itself as an internal R&D engine for small-molecule drug discovery that also works with external partners. Its partnership model is described as an ecosystem or networked approach to innovation in which risk and reward are shared and incentives aligned with collaborators.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Valo describes itself as re-imagining drug discovery by moving human causal biology to the start of the discovery process rather than later in the pipeline, and by integrating biology, chemistry and engineering functions within a single R&D engine.
Stated differentiators include starting discovery from human causal biology and large-scale de-identified patient records rather than from chemistry, use of causal inference and statistical genetics alongside proprietary knowledge graphs for target selection, and a closed-loop chemistry platform that models the attributes required for human success early in discovery.
Technology
AI/machine learning applied to large-scale human data, advanced causal inference methods, statistical genetics and proprietary knowledge graphs are used to identify patient subtypes, map them to biological pathways and prioritize therapeutic targets, with validation in human data and human tissue. Valo states it has access to more than 17 million de-identified patient records, some with 20-30 years of patient history and linked biobank samples. A closed-loop chemistry platform pairs predictive modeling with laboratory experimentation to explore chemical space, identify diverse lead compounds and iteratively refine models toward candidate molecules with a targeted clinical profile.
Go-to-market
Direct partnership and collaboration model, with prospective partners invited to contact the company; recruiting is conducted through the company's own careers channels.
Biopharmaceutical and life-science organizations seeking discovery collaborations, with therapies ultimately directed at patients in disease areas addressed by the company's pipeline.
Geography
Offices in Lexington, Massachusetts and New York, New York.
Risks & controversies
Valo has published a warning that job seekers have reported fraudulent employment offers and recruitment emails from parties impersonating Valo Health, noting the company does not request passport details, financial information or money from candidates and that legitimate company email addresses use the valohealth.com domain.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
In the news
SweGaN Raises an Additional $14 Million | Startbasestartbase.com · Aug 2026
Vertical Aerospace Secures Approximately $100 Million for Valo's Certification and Market Launch | Startbasestartbase.com · Aug 2026
Vertical Aerospace raises $100 million for Valo eVTOL - AeroTimeaerotime.aero · Aug 2026▸Research sources · 8
primary sources listed
- Valovalohealth.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Valo do?
- Valo is a drug discovery company combining real-world patient data, AI, causal inference and predictive chemistry.
- Who founded Valo?
- Valo was founded by David Berry.
- Who are Valo's investors?
- Valo's investors include Atinum Investment Co. Ltd., BioGenerator Ventures, Flagship Pioneering, Koch Disruptive Technologies.